Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015', provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview 8 Therapeutics Development 9 Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview 9 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies 10 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies 14 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development 16 Arrowhead Research Corporation 16 BioCryst Pharmaceuticals, Inc. 17 Cevec Pharmaceuticals GmbH 18 CSL Limited 19 Dyax Corp. 20 Global Blood Therapeutics, Inc. 21 iBio, Inc. 22 Isis Pharmaceuticals, Inc. 23 Pharming Group N.V. 24 ProMetic Life Sciences Inc. 25 Ra Pharmaceuticals, Inc. 26 Shire Plc 27 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 ARCF-12 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 avoralstat - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BCX-7353 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 BEL-0215 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 C1 esterase inhibitor (human) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 C1 esterase inhibitor (human) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 C1 esterase inhibitor (human) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 C1 esterase inhibitor (human) - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 C1 esterase inhibitor (recombinant) - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 CSL-312 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 icatibant acetate - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ISIS-PKKRx - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 lanadelumab - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 SHP-623 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecule to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Recent Pipeline Updates 65 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones 80 Featured News & Press Releases 80 Dec 07, 2015: European Medicines Agency Reaffirms Important Health Benefits and Safety of RUCONEST for Patients with Hereditary Angio-edema 80 Nov 09, 2015: Dyax Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting 80 Oct 08, 2015: BioCryst Announces Completion of Patient Enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients with HAE 82 Oct 08, 2015: BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353 82 Oct 08, 2015: FDA Grants RUCONEST (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity 83 Sep 30, 2015: Dyax Receives Positive Opinion for Orphan Medicinal Product Designation in the European Union for DX-2930 for the Treatment of Hereditary Angioedema 84 Aug 25, 2015: Shire to Attain Enhanced CINRYZE Manufacturing Flexibility and Capacity 84 Aug 12, 2015: Dyax Provides Update on DX-2930 Clinical and Commercial Supply Initiatives 85 Jul 20, 2015: HAEi Global Access Program for RUCONEST Now Live 85 Jul 07, 2015: Dyax Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema 86 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88
List of Tables
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Comparative Analysis by Late Stage Development, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Products under Development by Companies, H2 2015 (Contd..1) 15 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Research Corporation, H2 2015 16 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2015 17 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H2 2015 18 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Limited, H2 2015 19 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Dyax Corp., H2 2015 20 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics, Inc., H2 2015 21 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio, Inc., H2 2015 22 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 23 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group N.V., H2 2015 24 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc., H2 2015 25 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ra Pharmaceuticals, Inc., H2 2015 26 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H2 2015 27 Assessment by Monotherapy Products, H2 2015 28 Number of Products by Stage and Target, H2 2015 30 Number of Products by Stage and Mechanism of Action, H2 2015 32 Number of Products by Stage and Route of Administration, H2 2015 34 Number of Products by Stage and Molecule Type, H2 2015 36 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics - Recent Pipeline Updates, H2 2015 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
